1. Hydroxychloroquine / azithromycin in COVID-19: The association between time to treatment and case fatality rate. Roberto AlfonsoAccinelli et al. ELSEVIER. 14 september, 2021.
    https://doi.org/10.1016/j.tmaid.2021.102163
  2. Myocarditis After BNT162b2 and mRNA-1273 Vaccination. Kathryn F. Larson, et al. AHA Journals. June 16, 2021. https://doi.org/10.1161/CIRCULATIONAHA.121.055913
  3. The mechanisms of action of Ivermectin against SARS-CoV-2: An evidence-based clinical review article. Asiya Kamber Zaidi y Puya Dehgani-Mobaraki. Nature. June 15, 2021.
    https://doi.org/10.1038/s41429-021-00430-5
  4. Prevalence of Clinical and Subclinical Myocarditis in Competitive Athletes With Recent SARS-CoV-2 Infection. Curt J. Daniels, MD et al. JAMA Cardiology. May 27, 2021.
    https://doi.org/10.1001/jamacardio.2021.2065
  5. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Obbina Abani et al. THE LANCET. May 01, 2021.
    https://doi.org/10.1016/S0140-6736(21)00676-0
  6. Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial. Sanjay Ramakrishnan et al. The Lancet. April 09, 2021.
    https://doi.org/10.1016/S2213-2600(21)00160-0
  7. Post-COVID-19 paediatric inflammatory multisystem syndrome: association of ethnicity, key worker and socioeconomic status with risk and severity. Jonathan Broad et al. BMJ Journals. March 16, 2021. 
    https://doi.org/10.1136/archdischild-2020-320388
  8. Global trends in clinical studies of ivermectin in COVID-19. Morimasa Yagisawa et al. THE JAPANESE JOURNAL OF ANTIBIOTICS. March 10, 2021.
    http://jja-contents.wdc-jp.com/pdf/JJA74/74-1-open/74-1_44-95.pdf
  9. Neurologic Involvement in Children and Adolescents Hospitalized in the United States for COVID-19 or Multisystem Inflammatory Syndrome. Kerri L LaRovere et al. JAMA Neurology. March 05, 2021.
    https://doi.org/10.1001/jamaneurol.2021.0504
  10. Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19 A Randomized Clinical Trial. Eduardo López-Medina et al. JAMA Network. March 04, 2021. 
    https://doi.org/10.1001/jama.2021.3071
  11. The role of C-reactive protein as a prognostic marker in COVID-19. Dominic Stringer et al. International Journal of Epidemiology. March 03, 2021. 
    https://doi.org/10.1093/ije/dyab012
  12. The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: A pilot, double-blind, placebo-controlled, randomized clinical trial. Carlos Chaccour et al. EClinicalMedicine. February 01, 2021.
    https://doi.org/10.1016/j.eclinm.2020.100720
  13. Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody.  C. Garrett Rappazzo et al. Science. Januay 25, 2021. 
    https://doi.org/10.1126/science.abf4830
  14. Meta-analysis of randomized trials of ivermectin to treat SARS-CoV-2 infection. Andrew Hill, Ahmed Abdulamir et al. Research Square. January 19, 2021. 
    https://doi.org/10.21203/rs.3.rs-148845/v1
  15. Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers. Sheila F. Lumley et al. The New England Journal of Medicine. December 23, 2020. 
    https://doi.org/10.1056/NEJMoa2034545
  16. Rapid generation of durable B cell memory to SARS-CoV-2 spike and nucleocapsid proteins in COVID-19 and convalescence. Gemma E. Hartley et al. ScienceImmunology. December 22, 2020. 
    https://doi.org/10.1126/sciimmunol.abf8891
  17. Therapeutically administered ribonucleoside analogue MK-4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets. Robert M. Cox, Josef D. Wolf & Richard K. Plemper. December 03, 2020. 
    https://doi.org/10.1038/s41564-020-00835-2
  18. Why is COVID-19 less severe in children? A review of the proposed mechanisms underlying the age-related difference in severity of SARS-CoV-2 infections. Petra Zimmermann, Nigel Curtis. Archives of Disease in Childhood. December 01, 2020. 
    https://doi.org/10.1136/archdischild-2020-320338
  19. Respiratory function in patients post-infection by COVID-19: a systematic review and meta-analysis. R.Torres-Castro et al. ScienceDirect. November 25, 2020. 
    https://doi.org/10.1016/j.pulmoe.2020.10.013
  20. Therapeutic potential of ivermectin as add on treatment in COVID 19: A systematic review and meta-analysis. Biswa Mohan Padhy et al. J Pharm Pharm Sci. November 23, 2020. 
    https://doi.org/10.18433/jpps31457
  21. Diagnosis, Management, and Pathophysiology of Arterial and Venous Thrombosis in COVID-19. Gregory Piazza, MD, MS1; David A. Morrow, MD, MPH. JAMA Network. November 23, 2020. 
    https://doi.org/10.1001/jama.2020.23422
  22. Comprehensive health assessment three months after recovery from acute COVID-19. Bram van den Borst, MD, PhD et al. Clinical Infectious Diseases. November 21, 2020. 
    https://doi.org/10.1093/cid/ciaa1750
  23. Study of the Efficacy and Safety of Topical Ivermectin + Iota- Carrageenan in the Prophylaxis against COVID-19 in Health Personnel. Carvallo, Hector. Journal of Biomedical Research and Clinical Investigation. 20 noviembre del 2020. 
    http://doi.org/10.31546/2633-8653.1007
  24. Post-lockdown SARS-CoV-2 nucleic acid screening in nearly ten million residents of Wuhan, China. Shiyi Cao et al. Nature Commnunications. November 20, 2020. 
    https://doi.org/10.1038/s41467-020-19802-w 
  25. Pulmonary pathology of ARDS in COVID-19: A pathological review for clinicians. Sabrina Setembre Batah and Alexandre Todorovic Fabro. Elsevier. November 19, 2020. 
    https://doi.org/10.1016/j.rmed.2020.106239  
  26. Characteristics and outcomes of COVID-19 associated stroke: a UK multicentre case-control study. Perry RJ et al. BMJ Jounals. November 05, 2020. 
    http://dx.doi.org/10.1136/jnnp-2020-324927
  27. How COVID-19 has affected emergent visits to a Latin-American trauma department: Experience at a Peruvian national trauma referral center. Juan F. Pintado, et al. International Journal of the Care of the Injured. November 02, 2020. 
    https://doi.org/10.1016/j.injury.2020.11.005
  28. The Role of Vitamin D in The Age of COVID-19: A Systematic Review and Meta-Analysis. View ORCID ProfileRoya Ghasemian et al. medRxiv. October 26, 2020.
    https://doi.org/10.1101/2020.06.05.20123554
  29. Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans. Jeffrey Seow, et al. Nature microbiology. October 26, 2020. 
    https://doi.org/10.1038/s41564-020-00813-8
  30. Real-world effectiveness of hydroxychloroquine, azithromycin, and ivermectin among hospitalized COVID-19 patients: results of a target trial emulation using observational data from a nationwide healthcare system in Peru. Percy Soto-Becerra Sr.,  Carlos Culquichicon,  Yamilee Hurtado-Roca,  Roger V Araujo-Castillo. medRxiv. October 14, 2020.
    https://doi.org/10.1101/2020.10.06.20208066DATAMEDICA.FISS, como medio de información, no necesariamente se adhiere a  algunas opiniones que se vierten en el presente trabajo, cuando este trabajo es una revisión preliminar y no ha sido certificado por revisión por pares, por lo tanto aún no deben utilizarse para guiar la práctica clínica. 
  31. Acute hypokinetic-rigid syndrome following SARS-CoV-2 infection. Antonio Méndez-Guerrero et al. Neurology. October 13, 2020. 
    https://doi.org/10.1212/WNL.0000000000010282
  32. Acute hypokinetic-rigid syndrome following SARS-CoV-2 infection. Antonio Méndez-Guerrero et al. American Academy of Neurology. October 13, 2020. 
    https://doi.org/10.1212/WNL.0000000000010282
  33. Genomic evidence for reinfection with SARS-CoV-2: a case study. Richard L Tillett, PhD, et al. October 12, 2020. 
    https://doi.org/10.1016/S1473-3099(20)30764-7
  34. Clinical features and risk factors of COVID-19-associated liver injury and function: A retrospective analysis of 830 cases. FaxiangChen, et al. ELSEVIER. October 11, 2020. 
    https://doi.org/10.1016/j.aohep.2020.09.011 
  35. ICON (Ivermectin in COvid Nineteen) study: Use of Ivermectin is Associated with Lower Mortality in Hospitalized Patients with COVID19. Juliana Cepelowicz Rajter, et al. medRxiv. June 10, 2020. 
    https://doi.org/10.1101/2020.06.06.20124461DATAMEDICA.FISS, como medio de información, no necesariamente se adhiere a algunas opiniones que se vierten en el presente trabajo, cuando este trabajo es una revisión preliminar y no ha sido certificado por revisión por pares, por lo tanto aún no deben utilizarse para guiar la práctica clínica. 
  36. A review on obesity as a risk factor for mortality in COVID-19 disease. Janeth Tenorio-Mucha, Yamilée Hurtado-Roca. Acta Médica Peruana. October 07, 2020. 
    https://amp.cmp.org.pe/index.php/AMP/article/view/1197/1215
  37. Bromelain Inhibits SARS-CoV-2 Infection in VeroE6 Cells. Satish Sagar, et al. BioRxiv. September 16, 2020. 
    https://doi.org/10.1101/2020.09.16.297366
  38. COVID-19 and the Path to Immunity. David S. Stephens, et al. JAMA Network. September 11, 2020. 
    http://doi.org/10.1001/jama.2020.16656
  39. Immune-boosting role of vitamins D, C, E, zinc, selenium and omega-3 fatty acids: Could they help against COVID-19?. Hira Shakoor, et al. MATURITAS VOLUME 143, P1-9. January 01, 2021. 
    https://doi.org/10.1016/j.maturitas.2020.08.003
  40. Trajectories of vital signs in patients with COVID-19. Marco A.F. Pimentel, et al. European Resuscitation Council. September 01, 2020. 
    https://doi.org/10.1016/j.resuscitation.2020.09.002
  41. A COVID-19 vaccine candidate using SpyCatcher multimerization of the SARS-CoV-2 spike protein receptor-binding domain induces potent neutralising antibody responses. Tiong Kit Tan, et al. BioRxiv. August 31, 2020. 
    https://doi.org/10.1101/2020.08.31.275701
  42. Designing of epitope-based vaccine from the conserved region of spike glycoprotein of SARS-CoV-2. Vidhu Agarwal, Pritish Varadwaj, Akhilesh Tiwari. BioRxiv. August 27, 2020. 
    https://doi.org/10.1101/2020.08.27.269456
  43. Pediatric SARS-CoV-2: Clinical Presentation, Infectivity, and Immune Responses. Lael M. Yonker, MD, et al. The Journal od Pediatrics. August 19, 2020. 
    https://doi.org/10.1016/j.jpeds.2020.08.037
  44. Obesity and Mortality Among Patients Diagnosed With COVID-19: Results From an Integrated Health Care Organization. Sara Y Tartof, et al. Annals of Internal Medicine. August 12, 2020. 
    https://doi.org/10.7326/m20-3742
  45. Methylprednisolone as Adjunctive Therapy for Patients Hospitalized With COVID-19 (Metcovid): A Randomised, Double-Blind, Phase IIb, Placebo-Controlled Trial. Christiane Maria Prado Jeronimo, BSc, et al. Clinical Infectious Diseases. August 12, 2020. 
    https://doi.org/10.1093/cid/ciaa1177
  46. Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19. Takuya Sekine, et al. Cell. August 14, 2020.  
    https://www.sciencedirect.com/science/article/pii/S0092867420310084
  47. Symptom clusters in Covid19: A potential clinical prediction tool from the COVID Symptom study app. Carole H Sudre, et al. June 16, 2020. medRxiv preprint doi: 
    https://doi.org/10.1101/2020.06.12.20129056
  48. Effect of anakinra in COVID-19. Emma J Kooistra, Nicole J B Waalders, Matthijs Kox, Peter Pickkers. THE LANCET. July 24, 2020. 
    https://doi.org/10.1016/S2665-9913(20)30235-6
  49. Effect of Dexamethasone in Hospitalized Patients with COVID-19: Preliminary Report. Peter Horby, et al. NEJM. July 17, 2020. 
    https://doi.org/10.1056/NEJMoa2021436 
  50. Histopathology and genetic susceptibility in COVID‐19 pneumonia. Jan von der Thüsen, Menno van der Eerden. European Journal of Clinical Investigation. July 13, 2020. 
    https://doi.org/10.1111/eci.13259
  51. Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19). W. Joost Wiersinga, MD, PhD; Andrew Rhodes, MD, PhD; Allen C. Cheng, MD, PhD.; et al. A Review JAMA. July 10, 2020.
    https://doi.org/10.1001/jama.2020.12839
  52. Placental Pathology in COVID-19. Elisheva D Shanes, et al. American Journal of Clinical Pathology, Volume 154, Issue 1. July, 2020. 
    https://doi.org/10.1093/ajcp/aqaa089
  53. Proning in Non-Intubated (PINI) in Times of COVID-19: Case Series and a Review. Vishesh Paul, MD, Shawn Patel, DO, Michelle Royse, APRN, Mazen Odish, MD, Atul Malhotra, MD, Seth Koenig, MD. Journal of Intensive Care Medicine 2020, Vol. 35(8) 818-824. July 7, 2020. 
    https://doi.org/10.1177/0885066620934801
  54. The COVID-19 Cytokine Storm; What We Know So Far. Dina Ragab, Haitham Salah Eldin, Mohamed Taeimah, Rasha Khattab and Ramy Salem. Frontiers in Immunology. Volume 11, article 1446. June 16, 2020. 
    https://doi.org/10.3389/fimmu.2020.01446
  55. Symptom clusters in Covid19: A potential clinical prediction tool from the COVID Symptom study app. View ORCID ProfileCarole H Sudre, et al. MedRxiv. June 16, 2020. 
    https://doi.org/10.1101/2020.06.12.20129056
  56. UNDERSTANDING IMMUNE RESPONSES TO SARS-COV-2. Charu Kaushic. Publication #28 Charu Kaushic. McMaster Immunology Research Center (MIRC). July 06, 2020. 
    https://rsc-src.ca/en/voices/understanding-immune-responses-to-sars-cov-2
  57. Use of Tocilizumab for COVID-19-Induced Cytokine Release Syndrome A Cautionary Case Report. MD Jared RadbelEmail the author MD Jared Radbel, Navaneeth Narayanan, PharmD, MPHb, Pinki J. Bhatt, MD. CHEST 2020; 158(1):e15-e19. July, 2020. 
    https://doi.org/10.1016/j.chest.2020.04.024
  58. Phase 1/2 Study to Describe the Safety and Immunogenicity of a COVID-19 RNA Vaccine Candidate (BNT162b1) in Adults 18 to 55 Years of Age: Interim Report: Mark J. Mulligan, et al. medRxiv. July 01, 2020. 
    https://doi.org/10.1101/2020.06.30.20142570
  59. A comparative observational study on Ivermectin- Doxycycline and Hydroxychloroquine-Azithromycin therapy on COVID19 patients: Abu Taiub Mohammed Mohiuddin Chowdhury; Shahbaz, Mohammad Shahbaz, Md Rezaul Karim; Islam, Jahirul; Dan, Guo; He, Shuixiang. June, 2020. 
    https://doi.org/10.13140/RG.2.2.22193.81767/3
  60. COVID-19 Lung Injury is Not High Altitude Pulmonary Edema: Andrew M. Luks, Luanne Freer, Colin K. Grissom, Scott E. McIntosh, Robert B. Schoene, Erik R. Swenson, and Peter H. Hackett.High Altitude Medicine & Biology.Jun 2020.192-193. 
    http://doi.org/10.1089/ham.2020.0055
  61. COVID-19 in 7780 Pediatric Patients: A Systematic Review. Ansel Hoang, Kevin Chorath, Axel Moreira, Mary Evans, Finn Burmeister-Morton, Fiona Burmeister, et al. University of Texas. THE LANCET. June 26, 2020. 
    https://doi.org/10.1016/j.eclinm.2020.100433
  62. Immunology of COVID-19: Current State of the Science. Nicolas Vabret, et al. Immunity 52. June 16, 2020. 
    https://doi.org/10.1016/j.immuni.2020.05.002
  63. A compendium answering 150 questions on COVID‐19 and SARS‐CoV‐2: Carmen Riggioni, et al. EUROPEAN JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY. June 14, 2020. 
    https://doi.org/10.1111/all.14449
  64. Clinical manifestations of children with COVID‐19: A systematic review. Tiago H. de Souza MD, PhD; José A. Nadal MD, MSc;  Roberto J. N. Nogueira MD, PhD; Ricardo M. Pereira MD, PhD; Marcelo B. Brandão MD, PhD. Pediatric Pulmonology, Wiley. June 03, 2020. 
    https://doi.org/10.1002/ppul.24885
  65. Effect of Dexamethasone in Hospitalized Patients with COVID-19 – Preliminary Report. Dr. Peter Horby. medRxiv. June 22, 2020. 
    https://www.medrxiv.org/content/10.1101/2020.06.22.20137273v1
  66. The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China. Wen Zhang, et al. Clinical Immunology. Volume 214, May 2020, 108393. 
    https://www.sciencedirect.com/science/article/pii/S1521661620301984?via%3Dihub
  67. Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals. Grifoni et al., 2020, Cell 181, 1–13. June 25, 2020 ©2020 Elsevier Inc.
    https://doi.org/10.1016/j.cell.2020.05.015 
  68. COVID-19 with Different Severities: A Multicenter Study of Clinical Features. Yun Feng, et al. American Journal of Respiratory and Critical Care Medicine, Volume 201, Issue 11. June 01, 2020. 
    https://www.atsjournals.org/doi/10.1164/rccm.202002-0445OC
  69. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Leon Calya, Julian D. Drucea, Mike G. Cattona, David A. Jan, sbKylie M.Wagstaff. Antiviral Research. June 2020. 
    https://www.sciencedirect.com/science/article/pii/S0166354220302011
  70. Doxycycline and Hydroxychloroquine as Treatment for High-Risk COVID-19 Patients: Experience from Case Series of 54 Patients in Long-Term Care Facilities. Ahmad, Imtiaz et al. MedRxiv. May 22, 2020. 
    https://www.medrxiv.org/content/10.1101/2020.05.18.20066902v1.full.pdf
  71. Preliminary Report of the Favipiravir Observational Study in Japan. Yohei Doi, Masashi Kondo, Akifumi Matsuyama, Masahiko Ando, Yachiyo Kuwatsuka, Takuma Ishihara. May 15, 2020. 
    http://www.kansensho.or.jp/uploads/files/topics/2019ncov/covid19_casereport_en_200529.pdf
  72. Clinical characteristics, outcomes, and risk factors for mortality in patients with cancer and COVID-19 in Hubei, China: a multicentre, retrospective, cohort study. Prof Kunyu Yang, Yuhan Sheng, Prof Chaolin Huang, Prof Yang Jin, Nian Xiong, Ke Jiang, et al. May 29, 2020. 
    https://doi.org/10.1016/S1470-2045(20)30310-7 
  73. Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study. Jianbo Tian, Prof Xianglin Yuan, Jun Xiao, Prof Qiang Zhong, Chunguang Yang, Bo Liu, et al. The Lancet Oncology. May 29, 2020. 
    https://doi.org/10.1016/S1470-2045(20)30309-0
  74. Flatten the Curve! Modeling SARS-CoV-2/COVID-19 Growth in Germany on the County Level. Wieland Thomas. May 13, 2020. 
    https://doi.org/10.1101/2020.05.14.20101667
  75. Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients’ B cells. Yunlong Cao, Bin Su, Xianghua Guo, Chengfeng Qin, Ronghua Jin, X. Sunney Xie. May 17, 2020. 
    https://doi.org/10.1016/j.cell.2020.05.025
  76. Characteristics and Outcomes of Patients Hospitalized for COVID-19 and Cardiac Disease in Northern Italy. Riccardo M Inciardi,et al. European Heart Journal 41(19):1821-1829. May 14, 2020. 
    https://doi.org/10.1093/eurheartj/ehaa388
  77. Low dose of hydroxychloroquine reduces fatality of critically ill patients with COVID-19. Yu, B., Li, C., Chen, P., Zhou, N., Wang, L., Li, J., Jiang, H., and Wang, D.W. (2020). Sci China Life Sci 63. 15 May 2020. 
    https://doi.org/10.1007/s11427-020-1732-2
  78. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. Ruijin Hospital of China. Wei Tang and col. Published 14 May 2020.
    https://doi.org/10.1136/bmj.m1849
  79. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature Research. Gordon, D.E., Jang, G.M., Bouhaddou, M. et al. 30 April 2020.
    https://doi.org/10.1038/s41586-020-2286-9  
  80. Intervenciones farmacológicas para el tratamiento de la enfermedad por el coronavirus 2019 (COVID-19). Actualización al 22 de abril de 2020. Elaborado por Fabiola Huaroto, Karen Huamán, Catherine Bonilla, Maricela Curisinche y Ericson Gutiérrez. Lima: Unidad de Análisis y Generación de Evidencias en Salud Pública. Instituto Nacional de Salud, abril de 2020. Serie Revision Rápida Nº 07-2020. 
    https://web.ins.gob.pe/sites/default/files/Archivos/authenticated%2C%20administrator%2C%20editor/publicaciones/2020-03-31/RR_TRATAMIENTO%20COV-2019.pdf
  81. The ORF8 Protein of SARS-CoV-2 Mediates Immune Evasion through Potently Downregulating MHC-I. Yiwen Zhang, et al. May 24, 2020. 
    https://doi.org/10.1101/2020.05.24.111823
  82. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Yeming Wang, et al. April 29, 2020. 
    https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31022-9/fulltext
  83. Remdesivir: A Review of Its Discovery and Development Leading to Emergency Use Authorization for Treatment of COVID-19. Richard T. Eastman, Jacob S. Roth, Kyle R. Brimacombe, Anton Simeonov, Min Shen, Samarjit Patnaik, and Matthew D. Hall. ACS Central Science. May 4, 2020. 
    https://pubs.acs.org/doi/pdf/10.1021/acscentsci.0c00489?ref=vi-chemistry_coronavirus_research
  84. Update on treatment of COVID-19: ongoing studies between promising and disappointing results. Silvano Esposito, Silvana Noviello, Pasquale Pagliano. University of Salerno. Le Infezioni in Medicina, n. 2, 198-211, 2020. 
    https://www.infezmed.it/media/journal/Vol_28_2_2020_10.pdf
  85. COVID-19 pneumonia: ARDS or not?. Luciano Gattinoni, Davide Chiumello & Sandra Rossi. Critical Care volume 24, Article number: 154 (2020). April 16, 2020. 
    https://ccforum.biomedcentral.com/articles/10.1186/s13054-020-02880-z
  86. Vorläufiges Ergebnis und Schlussfolgerungen der COVID-19 Case-ClusterStudy (Gemeinde Gangelt). Dr. Hendrik Streeck, Dr. Gunther Hartmann,  Dr. Martin Exner, Dr. Matthias Schmid. April 09, 2020. 
    https://www.land.nrw/sites/default/files/asset/document/zwischenergebnis_covid19_case_study_gangelt_0.pdf
  87. The Approved Dose of Ivermectin Alone is not the Ideal Dose for the Treatment of COVID-19: Virginia D Schmith, Jie Zhou, Lauren RL Lohmer. April 26, 2020. 
    https://doi.org/10.1101/2020.04.21.20073262
  88. Potential role of zinc supplementation in prophylaxis and treatment of COVID-19. Amit Kumar, Yuichi Kubota, Mikhail Chernov, Hidetoshi Kasuya. Medical Hypotheses 144 (2020) 109848. May 15, 2020. 
    https://doi.org/10.1016/j.mehy.2020.109848
  89. Taype-Rondan A, Herrera-Añazco P, Málaga G. Sobre la escasa transparencia en los documentos técnicos para el tratamiento de pacientes con COVID-19 en Perú. Acta Med Peru. 2020;37(2):215-22. June 18, 2020. doi: 
    https://doi.org/10.35663/amp.2020.372.982